06/22/22 6:50 AMNasdaq : ANIP fda approvallow floatANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USPANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Clorazepate Dipotassium Tablets. The current annual U.S. market for Clorazepate Dipotassium Tablets is approximately $25.8 million, according to IQVIA/IMS Health, a leading healthcare data and...RHEA-AIneutral
06/21/22 7:03 AMNYSE, Nasdaq : VEEV, ANIP ANI Pharmaceuticals Adopts Veeva Commercial Cloud to Better Support Rare Disease PatientsANI Pharmaceuticals, Inc. (Nasdaq: ANIP) and Veeva Systems (NYSE: VEEV) today announced a collaboration to define andRHEA-AIpositive
06/02/22 4:05 PMNasdaq : ANIP acquisitionlow floatANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium AcquisitionANI Pharmaceuticals, Inc. today announced that it intends to cease operations at its Oakville, Ontario, Canada manufacturing plant by first quarter 2023. The Company will transition the majority of products manufactured or packaged in Oakville to one of its three U.S.- based manufacturing sites. The Company is seeking to find potential buyers for the Oakville...RHEA-AIpositive
06/01/22 4:15 PMNasdaq : ANIP fda approvallow floatANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USPANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Fludrocortisone Acetate Tablets USP, 0.1 mg. The current annual U.S. market for Fludrocortisone Acetate Tablets, 0.1 mg is approximately $24.2 million, according to IQVIA/IMS Health, a leading...RHEA-AIneutral
05/20/22 6:50 AMNasdaq : ANIP conferenceslow floatANI Pharmaceuticals to Present at Upcoming Healthcare Investor ConferencesANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at two upcoming conferences as follows:. ANI Pharmaceuticals is a diversified bio-pharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic...RHEA-AIneutral
05/10/22 6:50 AMNasdaq : ANIP low floatANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 MillionANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three months ended March 31, 2022. Driven by the Cortrophin Gel launch, we are increasing our full-year net revenue guidance and continuing to invest to bring this therapy to patients in need,” said Nikhil Lalwani, President and CEO of ANI. Net revenues were $64.5...RHEA-AIneutral
04/19/22 6:50 AMNasdaq : ANIP earningslow floatANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022ANI Pharmaceuticals, Inc. today announced that the Company will release its first quarter 2022 financial results on Tuesday, May 10, 2022. Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:. About ANI ANI...RHEA-AIneutral
04/11/22 6:50 AMNasdaq : ANIP low floatANI Pharmaceuticals Announces the Launch of Misoprostol TabletsANI Pharmaceuticals, Inc. today announced the launch of Misoprostol Tablets, 100 mcg and 200 mcg. The current annual U.S. market for Misoprostol Tablets, 100 mcg and 200 mcg is approximately $15.3 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider. ANI Pharmaceuticals, Inc. is a diversified bio-pharmaceutical company...RHEA-AIneutral
03/22/22 4:05 PMNasdaq : ANIP managementlow floatANI Pharmaceuticals Appoints Experienced Commercial Leader, Renee P. Tannenbaum, Pharm.D., MBA, to Board of DirectorsDr. Tannenbaum has over 35 years of management experience in the pharmaceutical industry. With her many accomplishments and proven track record of developing and implementing innovative commercial strategies, and driving growth, Dr. Tannenbaum will be a great asset to the Company, especially as we move forward with our commercialization of Purified...RHEA-AIvery positive
03/15/22 6:50 AMNasdaq : ANIP low floatANI Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; Strong Foundation in Place to Drive Sustainable GrowthANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and twelve months ended December 31, 2021. Received U.S. Food and Drug Administration approval for Purified Cortrophin™ Gel 80 U/mL, an adrenocorticotropic hormone indicated for the treatment of certain chronic autoimmune disorders, and subsequently...RHEA-AIneutral